secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2022-05-03T23:59:59+00:00
Accession:  0001193125-22-137551
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Intellia appoints Muna Bhanji as Class I director, expanding board to nine
--------------------------------------------------------------------------

- Muna Bhanji appointed to newly created Class I director seat, board expands from 8 to 9 members.
- Bhanji is founder of TIBA Global Access, former 30-year Merck senior VP for global market access & policy.
- Received option for 11,700 shares at $50.29/exercise price and 7,954 RSUs, vesting over 3 years.
- Term expires at 2023 annual meeting; Bhanji deemed independent under Nasdaq standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312522137551/0001193125-22-137551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312522137551/d317082d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-137551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer